Dimitrios Pectasides

Summary

Affiliation: University of Athens
Country: Greece

Publications

  1. pmc The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients
    Anna Koumarianou
    Fourth Department of Internal Medicine, Attikon University Hospital, Rimini 1 Street, 12462 Athens, Greece
    Exp Hematol Oncol 3:3. 2014
  2. ncbi request reprint Successful management of extracranial metastases from cerebral high-grade oligodendroglioma: report of a case with literature review
    D Pectasides
    Department of Medical Oncology A, Metaxa Cancer Hospital, Piraeus, Greece
    J BUON 7:273-6. 2002
  3. ncbi request reprint Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer
    Dimitrios Pectasides
    Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece
    Anticancer Res 36:6347-6356. 2016
  4. pmc Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or
    Dimitrios Pectasides
    Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, 11527, Greece
    BMC Cancer 15:384. 2015
  5. pmc Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review
    Gerasimos Aravantinos
    Second Department of Medical Oncology, Agioi Anargiroi Cancer Hospital, Κifisia, Athens, Greece
    J Ovarian Res 7:57. 2014
  6. pmc Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki Ring Road, 564 03 Thessaloniki, Macedonia, Greece
    BMC Cancer 14:515. 2014
  7. pmc Anti-N-methyl-D-aspartate receptor encephalitis presenting with acute psychosis in a preteenage girl: a case report
    Paraskevi Maggina
    1st Department of Pediatrics, P and A Kyriakou Children s Hospital, Athens, Greece
    J Med Case Rep 6:224. 2012
  8. pmc Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperat
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    BMC Cancer 13:163. 2013
  9. pmc Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    BMC Cancer 13:49. 2013
  10. pmc Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS)
    Vassiliki Kotoula
    Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Greece
    BMC Cancer 12:342. 2012

Collaborators

Detail Information

Publications130 found, 100 shown here

  1. pmc The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients
    Anna Koumarianou
    Fourth Department of Internal Medicine, Attikon University Hospital, Rimini 1 Street, 12462 Athens, Greece
    Exp Hematol Oncol 3:3. 2014
    ..The current study aimed to comparatively investigate the effect of metronomic and standard chemotherapy on the number and functionality of peripheral regulatory and effector T-cells in cancer patients...
  2. ncbi request reprint Successful management of extracranial metastases from cerebral high-grade oligodendroglioma: report of a case with literature review
    D Pectasides
    Department of Medical Oncology A, Metaxa Cancer Hospital, Piraeus, Greece
    J BUON 7:273-6. 2002
    ..She remains well and asymptomatic 18 months after the end of chemotherapy. We herein review the literature and discuss all the possible mechanisms for extracranial dissemination of primary brain tumours...
  3. ncbi request reprint Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer
    Dimitrios Pectasides
    Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece
    Anticancer Res 36:6347-6356. 2016
    ..The aim of this study was to evaluate the mRNA expression pattern of growth- and survival-related genes and assess their prognostic significance in patients with advanced pancreatic cancer...
  4. pmc Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or
    Dimitrios Pectasides
    Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, 11527, Greece
    BMC Cancer 15:384. 2015
    ..The aim of the trial was to compare two active adjuvant chemotherapy regimens in patients with early stage colorectal cancer (CRC)...
  5. pmc Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review
    Gerasimos Aravantinos
    Second Department of Medical Oncology, Agioi Anargiroi Cancer Hospital, Κifisia, Athens, Greece
    J Ovarian Res 7:57. 2014
    ..Data from phase III trials of newer anti-angiogenic agents in ovarian cancer are awaited. ..
  6. pmc Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki Ring Road, 564 03 Thessaloniki, Macedonia, Greece
    BMC Cancer 14:515. 2014
    ..However, the preferable taxane and optimal schedule of administration in a dose-dense regimen have not been defined yet...
  7. pmc Anti-N-methyl-D-aspartate receptor encephalitis presenting with acute psychosis in a preteenage girl: a case report
    Paraskevi Maggina
    1st Department of Pediatrics, P and A Kyriakou Children s Hospital, Athens, Greece
    J Med Case Rep 6:224. 2012
    ..This is the first report of anti-N-methyl-D-aspartate receptor encephalitis in a Greek pediatric hospital...
  8. pmc Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperat
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    BMC Cancer 13:163. 2013
    ..Limited information exists on the relationship of HER2/TOP2A gene status in the presence of centromere 17 (CEP17) gain with outcome of patients treated with anthracycline-containing adjuvant chemotherapy...
  9. pmc Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    BMC Cancer 13:49. 2013
    ..We studied EGFR-axis messenger RNA (mRNA) expression and RAS, RAF, PIK3CA mutations in order to identify additional biomarkers of cetuximab efficacy...
  10. pmc Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS)
    Vassiliki Kotoula
    Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Greece
    BMC Cancer 12:342. 2012
    ..The aim of this study was to determine the prognostic/predictive impact of B, E, R, T in routinely-treated NSCLC patients by taking into account the expression of these genes in the normal lung parenchyma...
  11. pmc XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
    Dimitrios Pectasides
    Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, University of Athens School of Medicine, Athens, Greece
    BMC Cancer 12:271. 2012
    ..The aim was to compare two standard chemotherapy regimens combined with bevacizumab as first-line treatment in patients with metastatic colorectal cancer...
  12. pmc HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
    George Fountzilas
    Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
    J Transl Med 10:10. 2012
    ..The aim of this study was to comprehensively evaluate the prognostic/predictive significance of the above parameters in early, high-risk breast cancer patients treated with epirubicin-based, dose-dense sequential adjuvant chemotherapy...
  13. pmc Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
    Helen Gogas
    First Department of Medicine, University of Athens, Medical School, Athens, Greece
    J Transl Med 8:108. 2010
    ..Specific CTLA-4 polymorphisms have previously shown an association with response to CTLA-4 blockade in patients with metastatic melanoma and the development of autoimmunity...
  14. pmc A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study
    Christos A Papadimitriou
    Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece
    BMC Med 9:10. 2011
    ..In this multicenter adjuvant phase III trial, we evaluated the addition of irinotecan to weekly 5FU plus LV in patients with stage II or III colon cancer...
  15. pmc Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas
    Panteleimon Kountourakis
    Second Department of Internal Medicine Propaedeutic, Athens University Medical School, Attikon University Hospital, Athens, Greece
    BMC Cancer 6:46. 2006
    ..In this study we sought to determine the pattern and the prognostic significance of HER-3 and HER-4 in colorectal adenocarcinoma...
  16. ncbi request reprint Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial
    D Pectasides
    First Department of Medical Oncology, Metaxa s Memorial Cancer Hospital, Piraeus, Greece
    Ann Oncol 13:243-50. 2002
    ..To evaluate the efficacy and toxicity of a combination of weekly docetaxel, gemcitabine and cisplatin in advanced transitional cell carcinoma (TCC) of the bladder...
  17. ncbi request reprint Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study
    D Pectasides
    1st Department of Medical Oncology, Metaxas Memorial Cancer Hospital, 51 Botassi, Str 18537, Piraeus, Greece
    Eur J Cancer 38:1194-200. 2002
    ..This combination of i.v. carboplatin AUC 2, docetaxel 20 mg/m(2) and irinotecan 60 mg/m(2) given weekly is highly effective in the treatment of chemotherapy-naïve advanced NSCLC. Toxicity was moderate, but manageable...
  18. ncbi request reprint Irinotecan and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. A phase II study of the Hellenic Cooperative Oncology Group
    D Pectasides
    1st Department of Medical Oncology, Metaxa s Memorial Cancer Hospital, Piraeus, Greece
    Anticancer Res 22:3501-6. 2002
    ..To evaluate the efficacy and tolerability of irinotecan plus vinorelbine every 2 weeks in patients with advanced non-small cell lung cancer (NSCLC), previously treated with platinum-based chemotherapy...
  19. ncbi request reprint Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study
    D Pectasides
    Second Department of Medical Oncology, Metaxas Memorial Cancer Hospital, Piraeus, Greece
    Ann Oncol 14:537-42. 2003
    ..The purpose of this study was to evaluate the efficacy and toxicity of oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes...
  20. ncbi request reprint Anti-beta2-glycoprotein I antibodies and ischemic stroke in a 20-month-old boy
    Eustathia Katsarou
    Department of Neurology, Panagiotis and Aglaia Kyriakou Children s Hospital, Athens, 11527 Greece
    Pediatrics 112:188-90. 2003
    ..This case supports the recommendation of others to search for these antibodies in the presence of strong clinical suspicion of antiphospholipid syndrome, when anticardiolipin antibodies and lupus anticoagulant tests are negative...
  21. ncbi request reprint Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study
    Dimitrios Pectasides
    2nd Department of Medical Oncology, Metaxas Memorial Cancer Hospital, 51 Botassi Street, 185 37 Piraeus, Greece
    Anticancer Res 23:4205-11. 2003
    ..To evaluate the efficacy and tolerability of irinotecan plus gemcitabine administered every two weeks in patients with advanced non-small cell lung cancer (NSCLC) previously treated with cisplatin-based chemotherapy...
  22. ncbi request reprint Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial
    Dimitrios Pectasides
    2nd Department of Medical Oncology, Metaxas Memorial Cancer Hospital, 51 Botassi St, 18537 Piraeus, Greece
    Anticancer Res 23:4239-44. 2003
    ..We investigated the efficacy and safety of 2 cycles of adjuvant chemotherapy with carboplatin, etoposide and bleomycin (CEB90) in patients with high-risk clinical stage I or stage IM non-seminomatous germ cell tumours (NSGCT)...
  23. ncbi request reprint Testicular function in patients with testicular cancer treated with bleomycin-etoposide-carboplatin (BEC(90)) combination chemotherapy
    Dimitrios Pectasides
    2nd Department of Medical Oncology, Metaxas Memorial Cancer Hospital, 51 Botassi St, 18537 Piraeus, Greece
    Eur Urol 45:187-93. 2004
    ..To investigate the impact of bleomycin-etoposide-carboplatin combination chemotherapy on long-term fertility in patients with testicular germ cell tumors...
  24. ncbi request reprint Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study
    D Pectasides
    Second Department of Medical Oncology, Metaxas Memorial Cancer Hospital, Piraeus, Greece
    Ann Oncol 15:493-7. 2004
    ..To investigate the efficacy and toxicity of the combination of gemcitabine and oxaliplatin (GEMOX) in patients with relapsed or cisplatin-refractory non-seminomatous germ cell tumors (NSGCT)...
  25. ncbi request reprint Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study
    Dimitrios Pectasides
    Second Department of Internal Medicine Propaedeutic, Athens University Medical School, Attikon University Hospital, Athens, Greece
    Eur Urol 46:216-21. 2004
    ..To investigate the efficacy and tolerability of the combination of oxaliplatin and irinotecan in patients with relapsed or cisplatin-refractory germ cell tumors (GCT)...
  26. ncbi request reprint Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study
    Dimitrios Pectasides
    Second Department of Internal Medicine Propaedeutic, Athens University Medical School, Attikon University Hospital, Athens, Greece
    Gynecol Oncol 95:165-72. 2004
    ....
  27. ncbi request reprint Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer
    Dimitrios Pectasides
    Second Department of Internal Medicine Propaedeutic, Athens University Medical School, Attikon University Hospital, Athens, Greece
    J Pharm Biomed Anal 37:171-6. 2005
    ..Their diagnostic accuracy, however, is considerably enhanced in patients not receiving hormonal therapy...
  28. ncbi request reprint Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial
    D Pectasides
    Second Department of Internal Medicine Propaedeutic, Athens University Medical School, Attikon University Hospital, 15342 Athens, Greece
    Ann Oncol 16:294-9. 2005
    ..The aim of this study was to evaluate whether docetaxel (taxotere) treatment with or without irinotecan improved patient outcomes with similar toxicity in recurrent non-small-cell lung cancer (NSCLC)...
  29. ncbi request reprint Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience
    Dimitrios Pectasides
    Second Department of Internal Medicine Propaedeutic, Oncology Section, University General Hospital Attikon, Gravias 5B, Aghia Paraskevi, 153 42 Athens, Greece
    Gynecol Oncol 97:436-41. 2005
    ..This study was undertaken to compare response and survival to platinum-based chemotherapy between patients with advanced stages III and IV mEOC and serous EOC (sEOC)...
  30. ncbi request reprint Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid
    Dimitrios Pectasides
    Second Department of Internal Medicine Propaedeutic, Athens University Medical School, Attikon University Hospital, Athens, Greece
    Anticancer Res 25:1457-63. 2005
    ..However, serum NTx has not yet been properly evaluated...
  31. ncbi request reprint Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature
    Dimitrios Pectasides
    Second Department of Internal Medicine Propaedeutic, Oncology Section, University General Hospital Attikon, Haidari, Athens, Greece
    Anticancer Res 25:3553-8. 2005
    ..A retrospective study of all patients diagnosed with brain metastases from EOC over the last 20 years, according to the Hellenic Cooperative Oncology Group (HeCOG) tumor registry, was conducted...
  32. ncbi request reprint Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience
    Dimitrios Pectasides
    Oncology Section, 2nd Department of Internal Medicine Propaedeutic, University of Athens Medical School, Attikon University Hospital, 1 Rimini Street, Haidari, Gravias 5B, Aghia Paraskevi, Athens 15342, Greece
    Gynecol Oncol 102:285-91. 2006
    ..This study was undertaken to compare response and survival to platinum-based chemotherapy between patients with advanced stage III and IV OCCC and serous EOC (sEOC)...
  33. ncbi request reprint Brain metastases from epithelial ovarian cancer: a review of the literature
    Dimitrios Pectasides
    Second Department of Internal Medicine, Propaedeutic, Oncology Section, Attikon University Hospital, 1 Rimini St, Haidari, Athens, Greece
    Oncologist 11:252-60. 2006
    ..Brain metastases from epithelial ovarian cancer (EOC) are rare. This report is based on a review of the literature...
  34. ncbi request reprint Merkel cell cancer of the skin
    D Pectasides
    Second Department of Internal Medicine, Oncology Section, University of Athens, Attikon University Hospital, Haidari, 1 Rimini, Athens, Greece
    Ann Oncol 17:1489-95. 2006
    ..Adjuvant chemotherapy (CT) should be considered as part of the initial management. In case of metastatic disease CT based on regimens used for small-cell lung cancer is the standard treatment of care...
  35. ncbi request reprint Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?
    D Pectasides
    Second Department of Internal Medicine, Athens University, Attikon University Hospital, Rimini 1, Haidari, Athens, Greece
    Expert Opin Pharmacother 7:975-87. 2006
    ..In this review, the data for second-line therapy in this latter group of patients will be summarised and recommendations for their optimal management will be made...
  36. ncbi request reprint HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy
    D Pectasides
    Second Department of Internal Medicine Propaedeutic, Oncology Section, Attikon University Hospital, Athens, Greece
    Anticancer Res 26:647-53. 2006
    ..The utility of serological assays for HER-2/neu in such patients was also studied...
  37. ncbi request reprint Dermatomyositis associated with breast cancer
    Dimitrios Pectasides
    Second Department of Internal Medicine Propaedeutic, Oncology Section, University Medical School, Attikon University Hospital, Athens, Greece
    Anticancer Res 26:2329-31. 2006
    ..In the present report, two new cases of DM associated with breast cancer are described, together with an extensive literature review...
  38. ncbi request reprint Systemic chemotherapy in locally advanced and/or metastatic bladder cancer
    D Pectasides
    Second Department of Internal Medicine, Propaedeutic, Oncology Section, Attikon University Hospital, Rimini 1, Haidari, 15342 Athens, Greece
    Cancer Treat Rev 32:456-70. 2006
    ..This review will summarize recent developments in the management of locally advanced (T4b, N 2-3) and/or metastatic (M1) bladder cancer...
  39. ncbi request reprint Fallopian tube carcinoma: a review
    Dimitrios Pectasides
    Second Department of Internal Medicine, Propaedeutic, Oncology Section, Attikon University Hospital, Rimini 1, Haidari, Athens, Greece
    Oncologist 11:902-12. 2006
    ..Primary fallopian tube carcinoma (PFTC) is a rare tumor that histologically and clinically resembles epithelial ovarian cancer (EOC). The purpose of this study is to review the current available literature data on PFTC...
  40. ncbi request reprint Treatment issues in clear cell carcinoma of the ovary: a different entity?
    Dimitrios Pectasides
    Second Department of Internal Medicine, Oncology Section, University of Athens, Greece
    Oncologist 11:1089-94. 2006
    ..Our goal was to review the clinical features and management of patients with OCCC...
  41. ncbi request reprint Maintenance or consolidation therapy in advanced ovarian cancer
    D Pectasides
    Second Department of Internal Medicine Propaedeutic, Oncology Section, Attikon University Hospital, Athens, Greece
    Oncology 70:315-24. 2006
    ..Notably, this randomized trial most likely did not offer any survival advantage, as it was closed prematurely by the Data Safety Monitoring Committee in accordance with the guidelines planned for interim analysis of primary end-points...
  42. ncbi request reprint Systemic therapy in metastatic or recurrent endometrial cancer
    D Pectasides
    Second Department of Internal Medicine, Oncology Section, University of Athens, Attikon University Hospital, Haidari, 1 Rimini, Athens, Greece
    Cancer Treat Rev 33:177-90. 2007
    ..Research in better understanding the signal transduction pathways in endometrial carcinogenesis will allow the development of specific and selective molecularly targeted inhibitors...
  43. ncbi request reprint Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience
    D Pectasides
    Second Department of Internal Medicine, Oncology Section, University General Hospital Attikon, Athens, Greece
    Int J Gynecol Cancer 17:1003-10. 2007
    ..001). In conclusion, younger women with EOC have significantly improved survival compared to older patients. Age, PS, stage of the disease at diagnosis, and residual disease are important independent predictors for survival...
  44. ncbi request reprint The management of stage I nonseminomatous testicular germ cell tumors
    Dimitrios Pectasides
    Second Department of Internal Medicine Propaedeutic, Athens University Medical School, Attikon University Hospital, Athens, Greece
    Oncology 71:151-8. 2006
    ....
  45. ncbi request reprint Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma
    Dimitrios Pectasides
    2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, Attikon University Hospital, Haidari, 1 Rimini, Athens, Greece
    Gynecol Oncol 108:47-52. 2008
    ....
  46. ncbi request reprint Granulosa cell tumor of the ovary
    D Pectasides
    Second Department of Internal Medicine, Propaeduetic, Oncology Section, University of Athens, Attikon University Hospital, Haidari, 1 Rimini, Athens, Greece
    Cancer Treat Rev 34:1-12. 2008
    ..Although overall response rate (RR) is high, the impact on disease-free or overall survival is unknown. Due to their tendency to recur years after the initial diagnosis, prolonged surveillance is essential...
  47. doi request reprint Merkel cell carcinoma of the skin: a retrospective study of 24 cases by the Hellenic Cooperative Oncology Group
    D Pectasides
    2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, Attikon University Hospital, Haidari, Athens, Greece
    Oncology 72:211-8. 2007
    ..The purpose of this retrospective study was to present the epidemiological and clinical characteristics of 24 patients with Merkel cell carcinoma of the skin (MCC) and their response to various therapeutic modalities...
  48. ncbi request reprint A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin
    D Pectasides
    Second Department of Internal Medicine, Propaedeutic, Oncology Section, Attikon University Hospital, Athens, Greece
    Anticancer Res 27:4411-7. 2007
    ..The objective of this study was to compare the efficacy of a disintegrating tablet of ondansetron (ODT) and the conventional tablet formulation of ondansetron (OT) in controlling nausea and vomiting in breast cancer patients...
  49. doi request reprint Carboplatin and paclitaxel in advanced or metastatic endometrial cancer
    D Pectasides
    Second Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, Attikon University Hospital, Haidari, 1 Rimini, Athens, Greece
    Gynecol Oncol 109:250-4. 2008
    ..The purpose of this study was to evaluate the activity and toxicity of carboplatin and paclitaxel combination in advanced or recurrent endometrial carcinoma...
  50. doi request reprint Germ cell tumors of the ovary
    D Pectasides
    Second Department of Internal Medicine, Propaeduetic, Oncology Section, University of Athens, Attikon University Hospital, Haidari, 1 Rimini, Athens, Greece
    Cancer Treat Rev 34:427-41. 2008
    ..Malignant ovarian germ cell tumors (MOGCTS) are rare but curable at all stages of disease. This review gives an outline of the management of this disease...
  51. ncbi request reprint Adult granulosa cell tumors of the ovary: a clinicopathological study of 34 patients by the Hellenic Cooperative Oncology Group (HeCOG)
    D Pectasides
    Second Department of Internal Medicine, Propaeduetic, Oncology Section, University of Athens, Attikon University Hospital, Haidari, Athens, Greece
    Anticancer Res 28:1421-7. 2008
    ..Granulosa cell tumors (GCT) are rare malignant neoplasms of the ovaries with, usually, indolent biological behavior...
  52. ncbi request reprint Primary non-Hodgkin's lymphoma of the bladder: report of two cases and review of the literature
    D Pectasides
    2nd Department of Internal Medicine, Oncology Section, University of Athens, Attikon University Hospital, Rimini 1, Haidari, Athens, Greece
    J BUON 13:277-9. 2008
    ..We present herein 2 cases of non-Hodgkin's lymphoma (NHL) of the bladder and discuss their clinical-pathological features and management...
  53. doi request reprint Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution
    Dimitrios Pectasides
    2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, Attikon University Hospital, Haidari, Athens, Greece
    Gynecol Oncol 110:299-303. 2008
    ..The purpose of this study was to evaluate the activity and toxicity of carboplatin, paclitaxel and pegylated liposomal doxorubicin combination in advanced or recurrent of the uterine carcinosarcoma...
  54. doi request reprint Chemotherapy for recurrent cervical cancer
    D Pectasides
    Second Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, Attikon University Hospital, Haidari, 1 Rimini, Athens, Greece
    Cancer Treat Rev 34:603-13. 2008
    ..Cervical cancer is the second most common cancer of women worldwide and one of the leading cause of death in relative young women. This review gives an outline of chemotherapy of advanced, persistent or recurrent cervical cancer...
  55. ncbi request reprint Primary ovarian lymphoma: report of two cases and review of the literature
    D Pectasides
    Second Department of Internal Medicine, Oncology Section, University General Hospital Attikon, Rimini 1, Haidari, Greece
    J Chemother 20:513-7. 2008
    ..Clinicians should be aware of its clinical manifestations and management since surgery alone often is not adequate treatment. Here, we present two cases of ovarian lymphoma and discuss what is known about ovarian lymphoma...
  56. ncbi request reprint Complete response after imatinib mesylate administration in a patient with chemoresistant stage IV seminoma
    D Pectasides
    Second Department of Internal Medicine, Propaedeutic, Oncology Section, General Hospital Attikon, University of Athens, Haidari, Athens, Greece
    Anticancer Res 28:2317-20. 2008
    ..The patient is under close follow-up, with no evidence of disease, 36 months after the completion of chemotherapy and 32 months post surgery...
  57. doi request reprint Current management of stage I testicular non-seminomatous germ cell tumours
    D Pectasides
    Second Department of Internal Medicine, Propaedeutic, Oncology Section, Attikon University General Hospital, Haidari, Athens, Greece
    Crit Rev Oncol Hematol 70:114-23. 2009
    ....
  58. doi request reprint Stage I testicular seminoma: management and controversies
    D Pectasides
    2nd Department of Internal Medicine, Propaedeutic, Oncology Section, Attikon University General Hospital, Haidari, Athens, Greece
    Crit Rev Oncol Hematol 71:22-8. 2009
    ..Standard treatment with radiotherapy is challenged by surveillance and chemotherapy. Toxicity issues and patients' preferences are considered when management decisions are made...
  59. doi request reprint Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors
    Dimitrios Pectasides
    Second Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, Attikon University Hospital, Athens, Greece
    Urol Oncol 28:617-23. 2010
    ..The efficacy and tolerability of M-TIP was evaluated as first-line treatment for patients with poor-risk germ cell tumors (GCT), according to International Germ Cell Cancer Collaborative Group (IGCCCG) criteria...
  60. doi request reprint Testicular function in poor-risk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy
    D Pectasides
    Second Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, Attikon University Hospital, Rimini 1, Haidari, Athens, Greece
    J Androl 30:280-6. 2009
    ..The majority of men with poor-risk germ cell tumors who were treated with the M-TIP regimen demonstrated recovery spermatogenesis after treatment, and Leydig cell function was unaffected...
  61. ncbi request reprint Analysis of 7 immunohistochemical markers in male germ cell tumors demonstrates the prognostic significance of p53 and MIB-1
    D Pectasides
    Second Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, Attikon University Hospital, Haidari, Athens, Greece
    Anticancer Res 29:737-44. 2009
    ..Various prognostic factors have been investigated in order to predict the minority of male germ cell tumor (GCT) patients who will develop resistant disease. However, no prognostic system has been proven accurate...
  62. ncbi request reprint Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG)
    D Pectasides
    2nd Department of Internal Medicine, Propaedeutic, Oncology Section, Attikon University Hospital, Rimini 1, Haidari, Athens, Greece
    Anticancer Res 29:745-51. 2009
    ..The aim of this retrospective study was to present the epidemiological, pathological and clinical characteristics and treatment results of Greek women with epithelial ovarian cancer (EOC)...
  63. ncbi request reprint Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience
    Dimitrios Pectasides
    Second Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, Attikon University Hospital, Haidari, Athens, Greece
    Anticancer Res 29:769-75. 2009
    ..The aim of this study was to evaluate the activity and toxicity of docetaxel, vinorelbine and oral estramustine in androgen-resistant prostate cancer (ARPC)...
  64. doi request reprint Carboplatin and paclitaxel in metastatic or recurrent cervical cancer
    Dimitrios Pectasides
    2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, Attikon University Hospital, Athens, Greece
    Int J Gynecol Cancer 19:777-81. 2009
    ..The purpose of this study was to evaluate the activity and toxicity of carboplatin and paclitaxel combination in advanced or recurrent carcinoma of the cervix...
  65. ncbi request reprint Gastric metastases originating from breast cancer: report of 8 cases and review of the literature
    D Pectasides
    Second Department of Internal Medicine, Attikon University Hospital, Rimini 1, Haidari, Athens, Greece
    Anticancer Res 29:4759-63. 2009
    ....
  66. doi request reprint Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma
    D Pectasides
    Second Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, University General Hospital Attikon, Rimini 1, Haidari, Athens, Greece
    Gynecol Oncol 118:52-7. 2010
    ..In this phase II study the efficacy and toxicity of an alternating chemotherapy regimen was examined in platinum-resistant relapsed epithelial ovarian cancer (EOC) patients...
  67. doi request reprint Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study
    Dimitrios Pectasides
    Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, University of Athens School of Medicine, Athens, Greece
    Oncol Rep 27:216-24. 2012
    ....
  68. ncbi request reprint Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2
    Paris A Kosmidis
    Hygeia Hospital, Tsoha 2 and Vas Sofias Ave, 11521, Athens, Greece
    Anticancer Res 32:175-81. 2012
    ..The purpose of this study was to compare two single agents paclitaxel (intravenous) versus vinorelbine (oral) in non-small cell lung cancer (NSCLC) patients with performance status (PS):2...
  69. doi request reprint Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial
    Helen Gogas
    1st Department of Medicine, Laiko General Hospital, University of Athens, Medical School, PO Box 14120, Athens 11510, Greece
    Breast Cancer Res Treat 132:609-19. 2012
    ..No DFS or OS benefit from the dose-dense sequential epirubicin and paclitaxel was detected when compared to the concurrent administration of the same drugs. No additional safety issues were raised with long-term follow-up...
  70. doi request reprint Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group
    Helen Gogas
    First Department of Medicine, Laiko General Hospital, Athens, Greece
    Clin Breast Cancer 10:230-7. 2010
    ..This phase II study sought to evaluate the efficacy of the paclitaxel-carboplatin combination as neoadjuvant chemotherapy in patients with locally advanced breast cancer (LABC)...
  71. doi request reprint Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma
    Dimitrios Pectasides
    Second Department of Internal Medicine Propaedeutic, Oncology Section, University General Hospital Attikon, Athens, Greece
    J Clin Oncol 27:939-44. 2009
    ....
  72. ncbi request reprint An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group
    D Pectasides
    HeCOG Data Office, Athens, Greece
    Anticancer Res 21:3005-10. 2001
    ..To validate these findings a randomized trial of gemcitabine and vinorelbine versus taxotere or best supportive care is required...
  73. doi request reprint Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression
    Evangelia Razis
    Third Department of Medical Oncology, Hygeia Hospital, Stavrou and Kifissias Ave, Maroussi, Athens, Greece
    Clin Breast Cancer 12:183-93. 2012
    ..Activation of this axis was found to be associated with determinants of poor prognosis but also with improved outcome in the human epidermal growth factor receptor 2 overexpressing subpopulation...
  74. ncbi request reprint Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors
    Dimitrios Farmakis
    Second Department of Medical Oncology, Metaxas Memorial Cancer Hospital, Piraeus, Greece
    Eur Urol 48:400-7. 2005
    ..Seminomas have generally a better prognosis than non-seminomatous tumors and salvage therapy is expected to cure about 50% of all cases...
  75. doi request reprint Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study
    Christos A Papadimitriou
    Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece
    Gynecol Oncol 111:27-34. 2008
    ..We administered the combination of paclitaxel, topotecan and carboplatin to patients with metastatic or recurrent carcinoma of the endometrium to evaluate its activity and to define its toxicity...
  76. ncbi request reprint Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women
    George Pentheroudakis
    Hellenic Cooperative Oncology Group HeCoG, Athens, Greece
    Breast Cancer Res Treat 97:237-44. 2006
    ..We sought to examine the epidemiology, clinical course, outcome and prognostic factors of this cohort with the hope to identify changing patterns, facilitate cost-effective follow-up and rationalize therapy of these patients...
  77. pmc A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
    Dimitrios Bafaloukos
    1st Oncology Department, Metropolitan Hospital, Athens, Greece
    BMC Med 8:3. 2010
    ..This randomized phase II study was undertaken in order to compare the combination of carboplatin and pegylated liposomal doxorubicin (LD) with carboplatin and paclitaxel (CP) in this setting...
  78. ncbi request reprint Prognostic significance of autoimmunity during treatment of melanoma with interferon
    Helen Gogas
    First Department of Medicine, Laiko Hospital, Athens, Greece
    N Engl J Med 354:709-18. 2006
    ..We assessed the prognostic significance of autoimmunity in patients with stage IIB, IIC, or III melanoma who were treated with high-dose adjuvant interferon alfa-2b...
  79. doi request reprint Developments in the systemic treatment of endometrial cancer
    Giannis Mountzios
    Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece
    Crit Rev Oncol Hematol 79:278-92. 2011
    ..Biomarkers with potent prognostic significance or predictive value for response to treatment are presented and novel molecular agents showing promising results in early clinical trials are discussed...
  80. ncbi request reprint Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study
    Dimosthenis V Skarlos
    Second Department of Medical Oncology, Henry Dunant Hospital, Athens, Greece
    Anticancer Res 25:3103-8. 2005
    ....
  81. ncbi request reprint Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas
    Panteleimon Kountourakis
    Second Department of Internal Medicine Propaedeutic, Athens University Medical School, Attikon University Hospital, Athens, Greece
    Cancer J 12:229-36. 2006
    ..The purpose of this study was to determine the prognostic impact of epidermal growth factor receptor (EGFR) and Her2/neu protein expression in colorectal cancer...
  82. doi request reprint Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy
    Olympia Tzaida
    Metaxas Cancer Hospital, Piraeus, Greece
    Oncology 72:388-96. 2007
    ..To assess the prognostic and predictive significance of HER-1/EGFR protein levels in high-risk patients with breast cancer treated with dose-dense sequential adjuvant chemotherapy...
  83. ncbi request reprint Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group
    A Bamias
    Department of Clinical Therapeutics Urology, Hygiene and Epidemiology, University of Athens School of Medicine, Athens, Greece
    J Clin Oncol 22:220-8. 2004
    ..The toxicity of this regimen compared favorably with that reported for MVAC. We thus designed a randomized phase III trial to compare DC with MVAC...
  84. ncbi request reprint Non small cell lung cancer in the elderly: clinico-pathologic, management and outcome characteristics in comparison to younger patients
    A Koumarianou
    Second Department of Internal Medicine Propaedeutic, Attikon University Hospital, Athens University, Athens, Greece
    J Chemother 21:573-83. 2009
    ....
  85. doi request reprint A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer
    Aristotelis Bamias
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Cancer Chemother Pharmacol 65:1009-21. 2010
    ..However, the possibility that a benefit by the addition of RT was not detected due to decreased power of the study should not be excluded...
  86. ncbi request reprint Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades
    A A Koumarianou
    Second Department of Internal Medicine Propaedeutic, Medical Oncology Unit, Attikon University Hospital, Athens University, Rimini 1, 12462 Athens, Greece
    Anticancer Res 27:1191-7. 2007
    ..Current controversial issues surrounding this disease, including the role of radiotherapy, positron emission tomography (PET), bone marrow biopsy and stem cell transplantation are discussed...
  87. doi request reprint Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients
    D Pectasides
    2nd Department of Internal Medicine, Propaedeutic, Oncology Section, University of Athens, Attikon University Hospital, Haidari, Athens, Greece
    Gynecol Oncol 115:97-101. 2009
    ....
  88. ncbi request reprint XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis
    Nikos Maniadakis
    Department of Health Services Organisation and Management, National School of Public Health, Athens, Greece
    Curr Med Res Opin 25:797-805. 2009
    ....
  89. ncbi request reprint Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study
    D Pectasides
    1Department of Medical Oncology, Metaxas Memorial Cancer Hospital, Piraeus, Greece
    J Clin Oncol 17:3816-21. 1999
    ..To evaluate the efficacy and toxicity of the combination of carboplatin, docetaxel, and gemcitabine in patients with advanced non-small-cell lung cancer (NSCLC)...
  90. ncbi request reprint Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group
    Helen Gogas
    First Department of Medicine, University of Athens, Athens, Greece
    Cancer Invest 22:832-9. 2004
    ..To evaluate the efficacy and toxicity of the combination of vinorelbine and interleukin (IL)-2 in patients with metastatic melanoma as second-line chemotherapy...
  91. ncbi request reprint Cisplatin-based chemotherapy for merkel cell carcinoma of the skin
    D Pectasides
    2nd Department of Internal Medicine, Propaeduetic, Oncology Section, University of Athens, Attikon University Hospital Haidari, 1 Rimini, Athens, Greece
    Cancer Invest 24:780-5. 2006
    ..Merkel cell carcinoma (MCC), a rare tumor of the skin with aggressive behavior, is usually fatal when advanced disease is present. The role of chemotherapy (CT) in the treatment of patients with MCC is unclear...
  92. ncbi request reprint Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG)
    G Papaxoinis
    Second Department of Internal Medicine, University General Hospital Attikon, University of Athens, Haidari, Greece
    Ann Oncol 19:780-6. 2008
    ..The aim was to examine characteristics and treatment results of patients with mucosa-associated lymphoid tissue (MALT) non-Hodgkin's lymphomas...
  93. ncbi request reprint Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group
    Paris A Kosmidis
    Hygeia Hospital, Athens, Greece
    J Thorac Oncol 2:135-40. 2007
    ..The primary endpoint was clinical benefit...
  94. doi request reprint Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    Crit Rev Oncol Hematol 66:237-47. 2008
    ..We sought to present epidemiology, management and outcome data on fit elderly patients with common metastatic cancers and to identify predictors of clinical benefit from palliative chemotherapy...
  95. doi request reprint Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
    Breast Cancer Res Treat 116:131-43. 2009
    ..We sought to study the predictive significance and correlations of transcriptional profiling of the ER, PgR and microtubule-associated protein Tau (MAP-Tau) genes in early breast cancer...
  96. doi request reprint Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study
    Gerasimos Aravantinos
    Agii Anargiri Cancer Hospital, Hellenic Cooperative Oncology Group, Hatzikonstanti 18, 115 24 Athens, Greece
    Eur J Cancer 44:2169-77. 2008
    ..The combination of Carboplatin and Paclitaxel is considered the standard of care as initial chemotherapy for Advanced Ovarian Cancer (AOC). We compared this regimen with the combination of Cisplatin, Paclitaxel and Doxorubicin...
  97. ncbi request reprint Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group
    Angelos K Koutras
    Division of Oncology, Department of Medicine, University Hospital of Patras, Patras Medical School, Rio, Greece
    Anticancer Res 28:2913-20. 2008
    ..The aim of this study was to determine whether myelosuppression in patients being treated with chemotherapy for advanced breast cancer has an impact on their prognosis...
  98. doi request reprint Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic C
    Dimosthenis V Skarlos
    Second Department of Medical Oncology, Metropolitan Hospital, Faliro, Greece
    Oncology 77:107-12. 2009
    ..Secondary objectives included the rate of severe neutropenia, treatment delays and dose reductions...
  99. doi request reprint Late complications of chemotherapy in testicular cancer
    Kyriaki Pliarchopoulou
    Second Department of Internal Medicine, Propaedeutic Oncology Section, University of Athens, Attikon University Hospital, Rimini 1, Haidari, Athens, Greece
    Cancer Treat Rev 36:262-7. 2010
    ..Therefore, close follow-up of the testicular cancer survivors as well as, focus on minimizing treatment complications through improvement of treatment strategies are warranted...
  100. doi request reprint Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study
    George Pentheroudakis
    Department of Medical Oncology, Ioannina University Hospital, Niarxou Avenue, 45500 Ioannina, Greece
    Breast Cancer Res Treat 127:179-93. 2011
    ..96 for OS, p = 0.46 for DFS). Transcriptional activity of β-tubulin isotype III in early breast cancer is an adverse prognostic factor, though not a predictive one for taxane efficacy...
  101. pmc Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin
    D Pectasides
    Department of Medical Oncology, Metaxas Memorial Cancer Hospital, Piraeus, Greece
    Br J Cancer 60:627-9. 1989
    ..We conclude that the combination of DTIC, VDS and CDDP is capable of producing a relatively high rate of response in patients with advanced metastatic malignant melanoma, but responses are short...